U.S. CDMOs with commercial manufacturing assets are likely to reach above market growth, according to Brian Scanlan, advisor of life sciences at Edgewater Capital Partners.
New funding reportedly supports Recipharm’s development of a digital manufacturing platform to advance continuous vaccine production and improve global access.
Join industry specialists as they share their insights, experiences, and strategies to enhance efficiency, reduce costs, and improve product quality in the production of non-traditional mAbs
